<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807911</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-0256</org_study_id>
    <nct_id>NCT00807911</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer</brief_title>
  <official_title>Randomized Phase II Study of Adjuvant Chemotherapy With 5-FU/Leucovorin vs. Oxaliplatin/5-FU/Leucovorin After Preoperative Chemoradiotherapy With Fluoropyrimidines Followed by Surgery in Patients With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the disease-free survival in patients with locally&#xD;
      advanced rectal cancer treated with preoperative chemoradiotherapy with fluoropyrimidines and&#xD;
      surgery followed by adjuvant combination chemotherapy with oxaliplatin/5-FU/Leucovorin vs&#xD;
      5-FU/Leucovorin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative chemoradiotherapy with fluoropyrimidines followed by surgery is one of the&#xD;
      standard treatments for patients with locally advanced rectal cancer; however, the role of&#xD;
      adjuvant chemotherapy is still controversial. The aim of this study is to investigate the&#xD;
      efficacy of adjuvant FOLFOX for rectal cancer who underwent fluoropyrimidine based&#xD;
      chemoradiotherapy and complete total mesorectal excision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival, pattern of failure,safety, quality of life</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant FL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant FL</intervention_name>
    <description>5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles</description>
    <arm_group_label>Adjuvant FL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant FOLFOX</intervention_name>
    <description>oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles</description>
    <arm_group_label>Adjuvant FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the rectum&#xD;
&#xD;
          2. Patients who treated with preoperative chemoradiation with fluoropyrimidines followed&#xD;
             by curative surgery without microscopic residual tumor.&#xD;
&#xD;
          3. AJCC/UICC pathologic stages of ypT3-4 or ypN+&#xD;
&#xD;
          4. Curative surgery not less than 3 and not more than 8 weeks prior to randomization&#xD;
&#xD;
          5. No prior chemotherapy, radiotherapy and immunotherapy except preoperative&#xD;
             chemoradiation for rectal cancer&#xD;
&#xD;
          6. ECOG PS 0-1&#xD;
&#xD;
          7. Adequate organ function&#xD;
&#xD;
          8. Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Macroscopic or microscopic evidence of remaining tumor&#xD;
&#xD;
          2. Any histologic feature other than adenocarcinoma or arisen from chronic inflammatory&#xD;
             bowel disease&#xD;
&#xD;
          3. More than 8 weeks after curative surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae Won Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National Unversity Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeonsei University Hosptial</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2008</study_first_posted>
  <last_update_submitted>January 27, 2019</last_update_submitted>
  <last_update_submitted_qc>January 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Tae Won Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>FOLFOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 14, 2021</submitted>
    <returned>March 5, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

